Lingke Pharmaceutical Co.
Latest round
- Series C
Last raised
- Sep 2023
Total raised
- $115M
Investors
- 15
About Lingke Pharmaceutical Co.
, Ltd. is a clinical-stage developer of novel medicines. The company was co-founded by Dr. Zhao-Kui Wan, Dr. Jun Wang, Dr. Michael Vazquez, and Mr. Jarod Chen. In 2020, the company had out-licensed a preclinical drug candidate to an American company and obtained a licensed RAS inhibitor from Kobe university & RIKEN research institute in Japan., Ltd. Lynk Pharmaceuticals' research and development techniques are used in Oncology, Immune inflammation, PROTAC, and Virtual screens. The company's pipeline products include Immune 1 to 4 an FIC and BIC/FIC potential, Oncology 1 to 3, an FIC potential, RAS, an FIC potential, and PROTAC or Novel Targets, an FIC potential. The company plans to conduct Phase I and II clinical trials for multiple programs in the research and development pipeline.
Who invested in Lingke Pharmaceutical Co.
15 investors across 6 rounds
See all investors in Lingke Pharmaceutical Co.
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Questions about Lingke Pharmaceutical Co.
Who invested in Lingke Pharmaceutical Co.?
Lingke Pharmaceutical Co. has 15 investors on record across 6 venture rounds. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has Lingke Pharmaceutical Co. raised?
Lingke Pharmaceutical Co. has raised 6 venture rounds. Sign up free to see how much each round raised and the total.
When did Lingke Pharmaceutical Co. last raise money?
Lingke Pharmaceutical Co.'s most recent round on record is a Series C, in Sep 2023.
What does Lingke Pharmaceutical Co. do?
Lingke Pharmaceutical Co. is a biotechnology company.
Where is Lingke Pharmaceutical Co. headquartered?
Lingke Pharmaceutical Co. is headquartered in Hangzhou, China.
Which VCs invest in companies like Lingke Pharmaceutical Co.?
Among active investors with capital left to deploy, Shanghai State-owned Capital Investment Leading Fund, Hui Hua Fund, Yufu Capital and ICBC Capital Management back biotechnology companies at Lingke Pharmaceutical Co.'s stage. Their profiles are linked below.
VCs backing biotechnology startups at Series C
Raising like Lingke Pharmaceutical Co.? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.